The Multiple Myeloma Landscape

The Multiple Myeloma Landscape

BLOOD CANCER: MULTIPLE MYELOMA Plasma cells are the antibody-producing cells of our immune system which happen to play a critical role in our defense against infections. In multiple myeloma, plasma cells begin to grow and divide in an uncontrolled manner, forming a...
Killing Cancer At Its Stem Cell Origin

Killing Cancer At Its Stem Cell Origin

Killing Cancer When it comes to killing cancer, eradicating every single cell is the goal. But did you know there are different kinds of cancer cells? One specific type, called cancer stem cells (CSC), is catching the eye of drug developers. Discovered more than a...
The Plight & Promise of p53

The Plight & Promise of p53

A Holy Grail? What if scientists could identify a mutated gene that accounts for more than half of all cancerous tumors? This gene would become a holy grail of cancer research. This gene exists, and it is called p53. The name p53 refers to its molecular...
Battling CLL: Venclexta

Battling CLL: Venclexta

 Pushing the Self-Destruct Button Breakthrough drug Venclexta charged onto the marketplace three months early to battle chronic lymphocytic leukemia. AbbVie’s (North Chicago, IL) and Roche’s (Basel, Switzerland) new therapy gained a quick approval after 80% of...
Killing Cancer At Its Stem Cell Origin

Feeding Cancer

The Metabolics Of Cancer Tackling cancer requires a multi-pronged strategy. Currently, many of the cancer drugs on the market work by inhibiting the signaling pathways that activate cell division. These pathways are often the root cause of cancer—a mutated gene leads...
New Hope For Basal Cell Carcinoma

New Hope For Basal Cell Carcinoma

The Science Behind The Latest FDA Approval Strong Phase II data launched Novartis’ (Basel, Switzerland) Odomzo to an accelerated FDA approval for basal cell carcinoma last week. The company skipped Phase III testing for the skin cancer drug because 58% of...